Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Agios Pharmaceuticals Inc (AGIO) reports a 51% increase in net Pyrukynd revenue and outlines promising future launches and ...

The Royalty Pharma deal ... recommending the approval of RYTELO for the treatment of transfusion-dependent anemia in adult patients with lower-risk myelodysplastic syndromes (MDS).

an anemia blood disorder. With these results, we expect an FDA filing for the drug in the back half of this year for approval. The company also sold its 15% royalty on a cancer drug, which ...

Research and Development (R&D) Expenses: R&D expenses were $82.8 million for the fourth quarter of 2024, compared to $77.5 million for the fourth quarter of 2023, and $301.3 million for the full year ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

Red blood cell hemoglobin and oxygen molecule dissolve Red blood cell dissolving with hemoglobin and oxygen molecules on both white and black background — concept anemia diagram stock videos & royalty ...

Find Anemia Patient stock video, 4K footage, and other HD footage from iStock. Get higher quality Anemia Patient content, for less—All of our 4K video clips are the same price as HD. Video Back Videos ...